CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer

Cancer-associated fibroblasts (CAFs) are one of the most significant components in the tumour microenvironment (TME), where they can perform several protumourigenic functions. Several studies have recently reported that CAFs are more heterogenous and plastic than was previously thought. As such, the...

Full description

Saved in:
Bibliographic Details
Published in:Trends in cancer Vol. 5; no. 11; p. 724
Main Authors: Pereira, Brooke A, Vennin, Claire, Papanicolaou, Michael, Chambers, Cecilia R, Herrmann, David, Morton, Jennifer P, Cox, Thomas R, Timpson, Paul
Format: Journal Article
Language:English
Published: United States 01.11.2019
Subjects:
Animals
Cancer-Associated Fibroblasts - pathology
Carcinoma, Pancreatic Ductal - pathology
Carcinoma, Pancreatic Ductal - therapy
Humans
Molecular Targeted Therapy - methods
Pancreatic Neoplasms - pathology
Pancreatic Neoplasms - therapy
Stromal Cells - pathology
Tumor Microenvironment
CAF heterogeneity
CAF subpopulations
cancer-associated fibroblasts
extracellular matrix (ECM)
pancreatic ductal adenocarcinoma (PDAC)
desmoplasia
stromal targeting
fibrosis
tumour–stroma crosstalk
ISSN:2405-8025, 2405-8025
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer-associated fibroblasts (CAFs) are one of the most significant components in the tumour microenvironment (TME), where they can perform several protumourigenic functions. Several studies have recently reported that CAFs are more heterogenous and plastic than was previously thought. As such, there has been a shift in the field to study CAF subpopulations and the emergent functions of these subsets in tumourigenesis. In this review, we explore how different aspects of CAF heterogeneity are defined and how these manifest in multiple cancers, with a focus on pancreatic ductal adenocarcinoma (PDAC). We also discuss therapeutic approaches to selectively target protumourigenic CAF functions, while avoiding normal fibroblasts, providing insight into the future of stromal targeting for the treatment of PDAC and other solid tumours.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2405-8025
2405-8025
DOI:10.1016/j.trecan.2019.09.010